[1]刘珂瑶,罗应楠,胡一雪,等.siRNA无载体递送研究进展[J].南京师大学报(自然科学版),2025,48(01):47-55.[doi:10.3969/j.issn.1001-4616.2025.01.007]
　Liu Keyao,Luo Yingnan,Hu Yixue,et al.Study Advance in siRNA Carrier-Free Delivery[J].Journal of Nanjing Normal University(Natural Science Edition),2025,48(01):47-55.[doi:10.3969/j.issn.1001-4616.2025.01.007]
点击复制

siRNA无载体递送研究进展()
分享到：

《南京师大学报（自然科学版）》[ISSN:1001-4616/CN:32-1239/N]

卷:
48
期数:
2025年01期
页码:
47-55
栏目:
生物学
出版日期:
2025-02-15

文章信息/Info

Title:
Study Advance in siRNA Carrier-Free Delivery
文章编号:
1001-4616(2025)01-0047-09
作者:
刘珂瑶1; 罗应楠1; 胡一雪2; 王东纳1; 张列峰1; 2
(1.南京师范大学食品与制药工程学院,江苏 南京 210023)
(2.南京师范大学生命科学学院,江苏 南京 210023)
Author(s):
Liu Keyao1; Luo Yingnan1; Hu Yixue2; Wang Dongna1;  ZhangLiefeng1; 2
(1.School of Food and Pharmaceutical Engineering,Nanjing Normal University,Nanjing 210023,China)
(2.School of Life Sciences,Nanjing Normal University,Nanjing 210023,China)
关键词:
小干扰RNA; 无载体递送; RNA干扰; 修饰策略; siRNA偶联物
Keywords:
siRNA; carrier-free delivery; RNA interference; modification strategy; siRNA conjugates
分类号:
R945
DOI:
10.3969/j.issn.1001-4616.2025.01.007
文献标志码:
A
摘要:
小干扰RNA(small interfering RNA,siRNA)作为一种能够特异性靶向基因沉默的重要分子,具有广阔的应用前景. 然而,siRNA的有效递送一直是其临床应用的关键问题之一. 传统的siRNA递送系统通常依赖于载体工具的辅助,但载体存在潜在的降解性、长期毒性和免疫反应等问题,限制了其在临床中的应用. 因此,无载体递送siRNA成为当前研究的热点之一. 本综述旨在回顾siRNA无载体递送研究的最新进展,包括其作用机制、递送策略以及递送优势等方面.
Abstract:
Small interfering RNA(siRNA),as an important molecule capable of specific gene silencing,holds great promise in various applications. However,the effective delivery of siRNA has always been one of the key issues for its clinical application. Traditional siRNA delivery systems often rely on carrier vehicles,but these carriers have potential issues such as degradation,long-term toxicity and immune response,which restrict their clinical use. Therefore,carrier-free delivery of siRNA has become one of the research hotspots. This review aims to summarize the latest advances in siRNA carrier-free delivery research,including mechanism of action,delivery strategies and delivery advantages.

参考文献/References:

[1]李怀东,李昕泽. 小干扰RNA研究概况[J]. 世界最新医学信息文摘,2019,19(35):116-117.
[2]陈忠斌,于乐成,王升启. RNA干扰作用(RNAi)研究进展[J]. 中国生物化学与分子生物学报,2002(5):525-528.
[3]SUBHAN M A,TORCHILIN V. siRNA based drug design,quality,delivery and clinical translation[J]. Nanomedicine:nanotechnology,biology and medicine,2020,29(1):102239.
[4]CORYDON I J,FABIAN-JESSING B K,JAKOBSEN T S,et al. 25 years of maturation:A systematic review of RNAi in the clinic[J]. Molecular therapy-nucleic acids,2023,33(3):469-482.
[5]DAR S A,THAKUR A,QURESHI A,et al. siRNAmod:A database of experimentally validated chemically modified siRNAs[J]. Scientific reports,2016,6(1):20031.
[6]SETTEN R L,ROSSI J J,HAN S. The current state and future directions of RNAi-based therapeutics[J]. Nature reviews drug discovery,2019,18(6):421-446.
[7]FRIEDRICH M,AIGNER A. Therapeutic siRNA:State-of-the-art and future perspectives[J]. BioDrugs,2022,36(5):549-571.
[8]张琼丹,陈朝霞,李芾瑶,等. siRNA纳米递送系统研究进展[J]. 生物化学与生物物理进展,2022,49(6):1018-1035.
[9]XU C,LI D,CAO Z,et al. Facile hydrophobization of siRNA with anticancer drug for non-cationic nanocarrier-mediated systemic delivery[J]. Nano letters,2019,19(4):2688-2693.
[10]CROOKE S T,BAKER B F,CROOKE R M,et al. Antisense technology:an overview and prospectus[J]. Nature reviews drug discovery,2021,20(6):427-453.
[11]FANG F,WANG S,SONG Y,et al. Continuous spatiotemporal therapy of a full-API nanodrug via multi-step tandem endogenous biosynthesis[J]. Nature communications,2023,14(1):1660.
[12]TAI W. Chemical modulation of siRNA lipophilicity for efficient delivery[J]. Journal of controlled release,2019,307(15):98-107.
[13]LEE J W,CHOI J,CHOI Y,et al. Molecularly engineered siRNA conjugates for tumor-targeted RNAi therapy[J]. Journal of controlled release,2022,351(18):713-726.
[14]李琛,司笑,李金波,等. 小干扰RNA药物的化学修饰及递送系统[J]. 化学学报,2023,81(9):1-18.
[15]SELVAM C,MUTISYA D,PRAKASH S,et al. Therapeutic potential of chemically modified siRNA:Recent trends[J]. Chemical biology & drug design,2017,90(5):665-678.
[16]MAGUREGUI A,ABE H. Developments in siRNA modification and ligand conjugated delivery to enhance RNA interference ability[J]. ChemBioChem,2020,21(13):1808-1815.
[17]JUAN M C,MEGAN K,VEERAJ S,et al. Albumin-binding RNAi conjugate for carrier free treatment of arthritis[J]. Biosystems engineering,2023,10(5):542971.
[18]LAURSEN M B,PAKULA M M,GAO S,et al. Utilization of unlocked nucleic acid(UNA)to enhance siRNA performance in vitro and in vivo[J]. Molecular biosystems,2010,6(5):862.
[19]FESLER A,HWANG G R,JU J. Development of novel 5-FU modified siRNA against BCL-2 with enhanced efficacy and vehicle-free cellular uptake[J]. Genes & diseases,2024,11(1):23-25.
[20]SOUTSCHEK J,AKINC A,BRAMLAGE B,et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs[J]. Nature,2004,432(7014):173-178.
[21]FERNANDEZ C,GIORGEES I,GOSS E,et al. Effective carrier-free gene-silencing activity of sphingosine-modified siRNAs[J]. Organic & biomolecular chemistry,2023,21(10):2107-2117.
[22]ZHENG Y,TAI W. Insight into the siRNA transmembrane delivery—from cholesterol conjugating to tagging[J]. WIREs nanomedicine and nanobiotechnology,2020,12(3):e1606.
[23]OSBORN M F,COLES A H,BISCANS A,et al. Hydrophobicity drives the systemic distribution of lipid-conjugated siRNAs via lipid transport pathways[J]. Nucleic acids research,2019,47(3):1070-1081.
[24]SUGO T,TERADA M,OIKAWA T,et al. Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles[J]. Journal of controlled release,2016,237(17):1-13.
[25]TAI W. Current aspects of siRNA bioconjugate for in vitro and in vivo delivery[J]. Molecules,2019,24(12):2211.
[26]YU Z,ZHANG X,PEI X,et al. Antibody-siRNA conjugates(ARCs)using multifunctional peptide as a tumor enzyme cleavable linker mediated effective intracellular delivery of siRNA[J]. International journal of pharmaceutics,2021,606(17):120940.
[27]WANG X,XIAO X,FENG Y,et al. A photoresponsive antibody-siRNA conjugate for activatable immunogene therapy of cancer[J]. Chemical science,2022,13(18):5345-5352.
[28]KLABENKOVA K,FOKINA A,STETSENKO D. Chemistry of peptide-oligonucleotide conjugates:A review[J]. Molecules,2021,26(17):5420.
[29]FU C,YU L,MIAO Y,et al. Peptide-drug conjugates(PDCs):a novel trend of research and development on targeted therapy,hype or hope?[J]. Acta pharmaceutica sinica B,2023,13(2):498-516.
[30]XIE X,LIN W,LI M,et al. Efficient siRNA delivery using novel cell-penetrating peptide-siRNA conjugate-loaded nanobubbles and ultrasound[J]. Ultrasound in medicine & biology,2016,42(6):1362-1374.
[31]YANG J,BAE H. Drug conjugates for targeting regulatory T cells in the tumor microenvironment:guided missiles for cancer treatment[J]. Experimental & molecular medicine,2023,55(9):1996-2004.
[32]SHARMA M,EL-SAYED N S,DO H,et al. Tumor-targeted delivery of siRNA using fatty acyl-CGKRK peptide conjugates[J]. Scientific reports,2017,7(1):6093.
[33]SIVAKUMAR P,KIM S,KANG H C,et al. Targeted siRNA delivery using aptamer-siRNA chimeras and aptamer-conjugated nanoparticles[J]. WIREs nanomedicine and nanobiotechnology,2019,11(3):e1543.
[34]ZHOU J,LAZAR D,LI H,et al. Receptor-targeted aptamer-siRNA conjugate-directed transcriptional regulation of HIV-1[J]. Theranostics,2018,8(6):1575-1590.
[35]JEONG E H,JEONG H,JANG B,et al. Aptamer-incorporated DNA holliday junction for the targeted delivery of siRNA[J]. Journal of industrial and engineering chemistry,2017,56(6):55-61.
[36]BEREZHNOY A,BRENNEMAN R,BAJGELMAN M,et al. Thermal stability of siRNA modulates aptamer-conjugated siRNA inhibition[J]. Molecular therapy-nucleic acids,2012,1(3):e51.
[37]CHEN S,LI D,DU X,et al. Carrier-free nanoassembly of doxorubicin prodrug and siRNA for combinationally inducing immunogenic cell death and reversing immunosuppression[J]. Nano today,2020,35(5):100924.
[38]SAW P E,YAO H,LIN C,et al. Stimuli-responsive polymer-prodrug hybrid nanoplatform for multistage siRNA delivery and combination cancer therapy[J]. Nano letters,2019,19(9):5967-5974.
[39]YANG Y,NING H,XIA T,et al. Electrostatic attractive self-delivery of siRNA and light-induced self-escape for synergistic gene therapy[J]. Advanced materials,2023,35(30):2301409.
[40]WITZIGMANN D,KULKARNI J A,LEUNG J,et al. Lipid nanoparticle technology for therapeutic gene regulation in the liver[J]. Advanced drug delivery reviews,2020,159(7):344-363.
[41]RANJBAR S,ZHONG X,MANAUTOU J,et al. A holistic analysis of the intrinsic and delivery-mediated toxicity of siRNA therapeutics[J]. Advanced drug delivery reviews,2023,201(10):115052.
[42]LEE J W,CHOI J,CHOI Y,et al. Molecularly engineered siRNA conjugates for tumor-targeted RNAi therapy[J]. Journal of controlled release,2022,351(21):713-726.
[43]ZHANG M M,BAHAL R,RASMUSSEN T P,et al. The growth of siRNA-based therapeutics:Updated clinical studies[J]. Biochemical pharmacology,2021,189(13):114432.

备注/Memo

备注/Memo:
收稿日期:2023-10-07.
基金项目:国家自然科学基金项目(21877061).
通讯作者:张列峰,博士,副教授,研究方向:蛋白质,核酸药物递送. E-mail:lfzhang@njnu.edu.cn
更新日期/Last Update: 2025-02-15